KR20220148299A - 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법 - Google Patents

가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법 Download PDF

Info

Publication number
KR20220148299A
KR20220148299A KR1020227036013A KR20227036013A KR20220148299A KR 20220148299 A KR20220148299 A KR 20220148299A KR 1020227036013 A KR1020227036013 A KR 1020227036013A KR 20227036013 A KR20227036013 A KR 20227036013A KR 20220148299 A KR20220148299 A KR 20220148299A
Authority
KR
South Korea
Prior art keywords
combination
statin
lipid
angptl3
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227036013A
Other languages
English (en)
Korean (ko)
Inventor
로버트 씨. 포디
윌리엄 제이. 사시엘라
다니엘 에이. 스웨머-가이프
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020247003356A priority Critical patent/KR20240019856A/ko
Publication of KR20220148299A publication Critical patent/KR20220148299A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227036013A 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법 Ceased KR20220148299A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247003356A KR20240019856A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662328823P 2016-04-28 2016-04-28
US62/328,823 2016-04-28
US201662348001P 2016-06-09 2016-06-09
US62/348,001 2016-06-09
US201762451310P 2017-01-27 2017-01-27
US62/451,310 2017-01-27
KR1020187034616A KR20190003679A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
PCT/US2017/029782 WO2017189813A1 (en) 2016-04-28 2017-04-27 Methods for treating patients with familial hypercholesterolemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034616A Division KR20190003679A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003356A Division KR20240019856A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20220148299A true KR20220148299A (ko) 2022-11-04

Family

ID=58692626

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227036013A Ceased KR20220148299A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
KR1020247003356A Pending KR20240019856A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
KR1020187034616A Ceased KR20190003679A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247003356A Pending KR20240019856A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
KR1020187034616A Ceased KR20190003679A (ko) 2016-04-28 2017-04-27 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법

Country Status (24)

Country Link
US (4) US20170312359A1 (OSRAM)
EP (1) EP3448426B1 (OSRAM)
JP (2) JP7201437B2 (OSRAM)
KR (3) KR20220148299A (OSRAM)
CN (1) CN109069641A (OSRAM)
AU (1) AU2017258105B2 (OSRAM)
CA (1) CA3021884A1 (OSRAM)
DK (1) DK3448426T3 (OSRAM)
ES (1) ES3032667T3 (OSRAM)
FI (1) FI3448426T3 (OSRAM)
HR (1) HRP20250797T1 (OSRAM)
HU (1) HUE071912T2 (OSRAM)
IL (2) IL293308B2 (OSRAM)
LT (1) LT3448426T (OSRAM)
MA (1) MA44764B1 (OSRAM)
MD (1) MD3448426T2 (OSRAM)
MX (1) MX2018012741A (OSRAM)
PL (1) PL3448426T3 (OSRAM)
PT (1) PT3448426T (OSRAM)
RS (1) RS66975B1 (OSRAM)
SI (1) SI3448426T1 (OSRAM)
SM (1) SMT202500230T1 (OSRAM)
WO (1) WO2017189813A1 (OSRAM)
ZA (1) ZA201806557B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3719128B1 (en) 2017-12-01 2025-01-15 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN112423795A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN118256498A (zh) 2019-05-22 2024-06-28 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
TWI887293B (zh) * 2019-11-07 2025-06-21 美商麥迪紐有限責任公司 用於治療心血管疾病之內皮脂酶抗體
WO2021154079A1 (en) 2020-01-29 2021-08-05 Rijksuniversiteit Groningen Means and methods for modulating lipid metabolism
EP4188372A1 (en) * 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3188213A1 (en) * 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途
CN116948030B (zh) * 2022-04-25 2024-11-19 武汉大学 抗asgr1单克隆抗体及其应用
EP4518969A1 (en) 2022-05-02 2025-03-12 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US730654A (en) * 1902-04-17 1903-06-09 John W Hornsey Hot-air furnace.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE357216T1 (de) * 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
HUE033960T2 (en) * 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
ES2677969T3 (es) * 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP3071198A1 (en) * 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
WO2015100394A1 (en) * 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP3845547A1 (en) * 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
CN109069868B (zh) * 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
AU2017248356A1 (en) * 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor

Also Published As

Publication number Publication date
LT3448426T (lt) 2025-07-10
IL262591B (en) 2022-07-01
IL293308A (en) 2022-07-01
HUE071912T2 (hu) 2025-10-28
US20170312359A1 (en) 2017-11-02
EP3448426B1 (en) 2025-05-28
US20230000976A1 (en) 2023-01-05
MA44764A (fr) 2019-03-06
IL262591A (en) 2018-12-31
MX2018012741A (es) 2019-05-16
JP2019514907A (ja) 2019-06-06
IL293308B1 (en) 2024-08-01
EP3448426A1 (en) 2019-03-06
PT3448426T (pt) 2025-06-04
SI3448426T1 (sl) 2025-07-31
MA44764B1 (fr) 2025-09-30
JP7201437B2 (ja) 2023-01-10
WO2017189813A1 (en) 2017-11-02
PL3448426T3 (pl) 2025-08-04
KR20240019856A (ko) 2024-02-14
JP7404471B2 (ja) 2023-12-25
CA3021884A1 (en) 2017-11-02
US20250332254A1 (en) 2025-10-30
SMT202500230T1 (it) 2025-07-22
ZA201806557B (en) 2019-07-31
AU2017258105A1 (en) 2018-11-22
CN109069641A (zh) 2018-12-21
DK3448426T3 (da) 2025-06-30
US20200061189A1 (en) 2020-02-27
MD3448426T2 (ro) 2025-09-30
IL293308B2 (en) 2024-12-01
ES3032667T3 (en) 2025-07-23
FI3448426T3 (fi) 2025-07-18
RS66975B1 (sr) 2025-07-31
KR20190003679A (ko) 2019-01-09
HRP20250797T1 (hr) 2025-08-29
AU2017258105B2 (en) 2024-09-05
JP2022177142A (ja) 2022-11-30

Similar Documents

Publication Publication Date Title
JP7404471B2 (ja) 家族性高コレステロール血症を有する患者を処置するための方法
US12281173B2 (en) Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
KR102860143B1 (ko) Angptl3의 억제제를 투여함으로써 죽상 동맥경화증을 치료하거나 예방하기 위한 방법
KR20180132843A (ko) Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
US20240197870A1 (en) Methods for treating patients with refractory hypercholesterolemia
HK40003056B (en) Methods for treating patients with familial hypercholesterolemia
HK40003056A (en) Methods for treating patients with familial hypercholesterolemia
EA042876B1 (ru) Способы лечения пациентов с семейной гиперхолестеринемией

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221017

Application number text: 1020187034616

Filing date: 20181128

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230201

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230701

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230330

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20221115

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20231027

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230921

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230701

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230330

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221115

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20240129

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20231027

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20230701

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2024101000225

Request date: 20240129

J301 Trial decision

Free format text: TRIAL NUMBER: 2024101000225; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20240129

Effective date: 20241128

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20241128

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20240129

Decision date: 20241128

Appeal identifier: 2024101000225